Contineum Therapeutics, Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Consensus

—

Average target

$18.67

Implied upside

—

Analysts

—

Why Is CTNM Down Today?

Contineum Therapeutics shares slumped today following disappointing Phase 2 trial results for its flagship depression drug JNJ-5120/PIPE-307, a Johnson & Johnson partnership. The stock declined 0.43% intraday with a more significant 10% after-hours drop, as the MOONLIGHT-1 trial failed to meet its primary efficacy endpoint, raising questions about the company's pipeline prospects.

Bottom line: Contineum Therapeutics faces a critical inflection point following the Phase 2 trial failure for its lead depression candidate, driving today's decline and significant after-hours selling. While analyst support remains intact, investors should monitor upcoming exploratory endpoint data and any commentary from Johnson & Johnson regarding the partnership's future, as these developments will likely determine whether CTNM can recover from current depressed valuations.